Research To Practice | Oncology Videos

Featuring perspectives from Dr Kathleen N Moore, moderated by Dr Stephen "Fred" Divers CME information and select publications

Featuring perspectives from Dr Stephen T Oh, moderated by Dr Stephen "Fred" Divers CME information and select publications

Featuring an interview with Dr Seth Wander, including the following topics: Design of SERENA-6, a Phase III switching trial of camizestrant for ESR1-mutant breast cancer during first-line treatment Turner N et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol 2023;19(8):559-73. Abstract (0:00) EMERALD trial analysis of patient-reported outcomes with oral elacestrant compared to standard of care endocrine therapy for ER-positive, HER2-negative advanced or metastatic breast cancer Cortes J et al. EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy. ESMO Breast 2023;Abstract 188O. (5:50) Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2-directed therapy, with or without abemaciclib, for ER-positive, HER2-positive advanced breast cancer Bhave MA et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study. ASCO 2024;Abstract 1027. (9:43) CME information and select publications

Featuring perspectives from Dr Harry Paul Erba, moderated by Dr Stephen "Fred" Divers CME information and select publications

Featuring perspectives from Dr Edward B Garon, moderated by Dr Stephen "Fred" Divers CME information and select publications

Featuring perspectives from Dr Heather Wakelee, including the following topics: Introduction (0:00) Cases: A man in his late 50s with metastatic carcinoma of the lung, no actionable genomic alteration (AGA), PD-L1-negative, and a man in his early 60s with metastatic squamous cell carcinoma of the lung, PD-L1-negative — Brian P Mulherin, MD and Taral Patel, MD (8:08) Case: A man in his late 60s presenting with metastatic adenocarcinoma of the lung, multiple bone metastases, no AGA; PD-L1 20%; enrolled on ECOG-EA5163 — Priya Rudolph, MD, PhD (21:45) Current and Emerging Immunotherapeutic Strategies for Metastatic Non-Small Cell Lung Cancer (mNSCLC) (30:55) Case: An African American man in his early 60s with 6.2-cm squamous cell carcinoma of right upper lung receives neoadjuvant treatment as per CheckMate 816 — Dr Rudolph (39:16) Case: A man in his late 60s with pT2aN0 invasive adenocarcinoma of the right lower lung, no AGA; PD-L1 5% — Zanetta S Lamar, MD (44:57) Antibody-Drug Conjugates and Other Management Approaches for mNSCLC without AGAs (48:51) Case: A woman in her early 60s diagnosed in 2014 with metastatic adenocarcinoma of the lung treated on ECOG 5508 (carboplatin/paclitaxel/bevacizumab) receives nivolumab on disease progression — Dr Rudolph (56:35) CME information and select publications

Featuring perspectives from Dr Priyanka Sharma and Dr Sara M Tolaney, including the following topics: Introduction: Metastatic Triple-Negative Breast Cancer (mTNBC) — The Patient Perspective (0:00) Selection and Sequencing of Antibody-Drug Conjugates (5:09) Dosing and Tolerability of Sacituzumab Govitecan; Use of Anthracyclines (14:39) Case: A woman in her early 60s with relapsed TNBC (HER2 2+) who experiences disease progression on T-DXd (Grade 2 interstitial lung disease) and receives sacituzumab govitecan — Shaachi Gupta, MD, MPH (22:04) Discussing Palliative and End-of-Life Care (32:40) PARP Inhibitors for TNBC with Somatic versus Germline Mutations; Cytopenias with PARP Inhibitors (37:53) The "Art of Oncology" — Building Trust with Patients and Family Members (45:05) Case: A woman in her mid 60s with recurrent TNBC with extensive chest wall involvement — Dr Gupta (48:44) Case: A man in his mid 40s with multiregimen-refractory AR-positive TNBC with an ERBB2 exon 20 insertion mutation — Dr Gupta (52:53) CME information and select publications

Featuring perspectives from Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile M Shammo, including the following topics: Introduction: Paroxysmal Nocturnal Hemoglobinuria (PNH) and the General Medical Oncologist Diagnosis of and myths and misperceptions about PNH (0:00) Overview — Biology and Pathophysiology Role of complement activation in PNH; classification and clinical presentation (7:00) PNH treatments and their complement targets (21:37) Current Management Approaches Mechanistic similarities and differences between crovalimab and other available C5 inhibitors; potential practical advantages of crovalimab (24:56) Timing for initiation of treatment for PNH (32:08) Management of clinically significant extravascular hemolysis and residual anemia in patients with PNH receiving C5 inhibitor therapy (43:08) Risk of evolution to aplastic anemia or myeloid malignancy (45:54) Clinical trial database establishing the efficacy and safety of the C5 complement inhibitors eculizumab and ravulizumab for PNH (48:47) Activity and safety of and clinical experience with crovalimab (53:03) Monitoring and management of PNH in pregnant patients (58:37) Case Presentations Case: A woman in her early 30s who receives a new diagnosis of classical PNH with symptomatic anemia — Dr Gerber (1:03:44) Case: A man in his early 30s with PNH initially treated with eculizumab who is transitioned to ravulizumab — Dr Koprivnikar (1:17:32) Case: A woman in her early 50s with a remote history of aplastic anemia — Dr Gerber (1:32:24) Case: A woman in her late 20s with PNH receiving active C5 inhibitor therapy who wishes to discuss alternative treatment options — Dr Koprivnikar (1:38:00) CME information and select publications

Practical Perspectives: Investigators Discuss the Current Management of Paroxysmal Nocturnal Hemoglobinuria — Jamile M Shammo, MD CME information and select publications

Featuring an interview with Dr Seth Wander, including the following topics: ASCO Guidelines Rapid Recommendations Update for Testing for ESR1 Mutations (0:00) Real-world elacestrant use patterns and genomic biomarkers (4:43) Circulating tumor DNA (ctDNA) analyses with imlunestrant in the EMBER Phase I study (8:50) CME information and select publications

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Current Therapeutic Approaches for Multiple Myeloma — Dr Lonial (0:37) Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Raje (22:53) CME information and select publications

Featuring perspectives from Dr Suresh S Ramalingam and Dr Gregory J Riely, including the following topics: Introduction: Tumor Treating Fields (0:00) Nontargeted Therapy for Lung Cancer — Dr Ramalingam (4:02) Targeted Therapy for Non-Small Cell Lung Cancer — Dr Riely (33:50) CME information and select publications

Featuring perspectives from Dr Nicole Lamanna, including the following topics: Introduction (0:00) Case: A man in his late 60s with IGHV-mutated chronic lymphocytic leukemia (CLL) (trisomy 12) and progressive adenopathy — Bhavana (Tina) Bhatnagar, DO (1:22) Case: A woman in her mid 70s with IGHV-unmutated, del(13q) CLL and fatigue — Erik Rupard, MD (19:57) Case: A woman in her mid 80s with del(13q) CLL under watchful waiting develops progressive symptoms — Shams Bufalino, MD (30:00) Case: A woman in her early 60s diagnosed with small lymphocytic leukemia (SLL) now with disease progression on ibrutinib — Warren S Brenner, MD (33:08) Current role of pirtobrutinib; CAR T-cell therapy; Richter's transformation — Dr Brenner (36:04) Case: A man in his mid 40s with SLL who received second-line venetoclax/rituximab — Yanjun Ma, MD (50:01) CME information and select publications

Featuring a slide presentation and related discussion from Dr Emanuela Palmerini, including the following topics: Background, diagnosis and disease course of tenosynovial giant cell tumor (TGCT) (0:00) Clinical data supporting systemic therapy for TGCT (10:19) Clinical data on emerging therapies for TGCT (17:28) Conclusion and future directions for TGCT (22:02) CME information and select publications

Featuring an interview with Dr Emanuela Palmerini, including the following topics: Pathology, clinical presentation, diagnosis and workup of tenosynovial giant cell tumor (TGCT) (0:00) Local therapies for and surgical management of TGCT (20:28) Available systemic therapies for TGCT (30:31) Investigational agents under development for TGCT (49:13) Patient case presentations (55:54) CME information and select publications

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Updates in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma — Dr Kahl (1:10) Updates in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Dr S Smith (33:32) CME information and select publications

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Role of Hormonal Therapy in Prostate Cancer Management — Dr M Smith (10:54) Other Available and Emerging Therapeutic Approaches — Dr Srinivas (37:03) CME information and select publications

Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities — Hope S Rugo, MD CME information and select publications

Featuring perspectives from Dr Komal Jhaveri and Dr Hope S Rugo, including the following topics: Introduction: PI3K/AKT/PTEN Pathway and Resistance to Endocrine Therapy (0:00) First-Line Therapy for HR-Positive Metastatic Breast Cancer (mBC) Harboring PI3K/AKT/PTEN Mutations (7:04) Treatment Options for Recurrent mBC with PI3K/AKT/PTEN Mutations (24:11) Beyond the Guidelines Survey (35:36) Faculty Case Presentations (51:27) CME information and select publications

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Nontargeted Therapy for Lung Cancer — Dr Goldberg (9:07) Targeted Therapy for Non-Small Cell Lung Cancer — Dr Sabari (51:19) CME information and select publications

Featuring perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Hormone Receptor-Positive Breast Cancer — Dr O'Shaughnessy (10:45) Management of Relapsed/Refractory HR-Positive Metastatic Breast Cancer — Dr Wander (40:47) CME information and select publications

What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma — Gilles Salles, MD, PhD CME information and select publications

Featuring an interview with Dr Gilles Salles, including the following topics: Epigenetic modifications and the role of EZH2 in the pathobiology of follicular lymphoma (FL) (0:00) Natural history of FL and current treatment landscape in the first-line setting (5:20) Testing approaches for the detection of EZH2 mutations (14:37) Mechanism of action of the EZH inhibitors tazemetostat and valemetostat (18:31) Tazemetostat monotherapy as treatment for relapsed/refractory FL (20:58) Ongoing evaluation of novel treatment approaches with tazemetostat for FL and other lymphomas (25:31) Approved indications for tazemetostat for wild-type FL and FL with EZH2 mutations; sequencing of tazemetostat with bispecific antibodies and CAR T-cell therapy (34:07) Available clinical data with the novel dual EZH1/EZH2 inhibitor valemetostat (42:37) Personal experience with CAR T-cell therapy and perspectives on possible underlying reasons for the development of T-cell lymphoma in patients receiving this treatment (44:35) Management of FL in patients who experience relapse within 24 months of receiving treatment (POD24) (48:25) Myths or misperceptions associated with tazemetostat and other therapies approved in the relapsed FL setting (52:15) Perspectives on the future treatment landscape of FL (54:29) CME information and select publications

Featuring an interview with Dr Stephen V Liu, including the following topics: Management of localized non-small cell lung cancer (NSCLC) (0:00) First-line treatment of advanced NSCLC (10:53) Targeted therapy for patients with NSCLC and actionable genomic alterations (30:24) Recent FDA approvals for NSCLC (37:49) Recent advances in small cell lung cancer (47:14) Lurbinectidin in combination with atezolizumab as front-line maintenance therapy for patients with early-stage SCLC (52:33) CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr Philip A Philip, including the following topics: Introduction (0:00) Colorectal Cancer, Anal Cancer and Pancreatic Cancer — Dr Philip (1:56) Gastroesophageal Cancers, Hepatocellular Cancer and Biliary Tract Cancers — Dr Bekaii-Saab (41:48) CME information and select publications

Featuring perspectives from Prof Francois-Clement Bidard and Dr Kevin Kalinsky, including the following topics: Introduction: Confronting Metastatic Breast Cancer (mBC) (0:00) Mechanisms of Resistance to Endocrine Therapy in HR-Positive mBC; Use of Oral Selective Estrogen Receptor Degraders (SERDs) — Dr Kalinsky (13:18) Ongoing Evaluation of Early Therapeutic Switching for HR-Positive mBC Harboring ESR1 Mutations — Prof Bidard (35:52) CME information and select publications

Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma | Faculty Presentation — Michael Wang, MD CME information and select publications.

Featuring perspectives from Dr Tycel Phillips and Dr Michael Wang, including the following topics: Introduction: Interface Between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (0:00) Key Datasets — Overview and First-Line Therapy (7:16) Faculty Case Presentations — Dr Phillips (27:03) Key Datasets — Relapsed/Refractory Disease (35:40) Faculty Case Presentations — Dr Wang (48:06) CME information and select publications

Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics: Targeted therapies for ER-positive breast cancer (0:00) Clinical data with oral selective estrogen receptor degraders (2:13) Biological rationale for and mechanism of action of proteolysis-targeting chimeras (PROTACs) (7:07) Emerging data with PROTACs for ER-positive advanced breast cancer (9:17) Future directions with PROTACs for breast cancer (19:21) CME information and select publications

Featuring an interview with Dr Erika Hamilton, including the following topics: Pathophysiology and pharmacology of ER-positive breast cancer treatment (0:00) Clinical evidence available with oral selective estrogen receptor degraders (3:46) Mechanism of action of proteolysis-targeting chimeras (PROTACs) (13:22) PROTACs currently in clinical development (16:39) Case: A woman in her late 30s with HR-positive, HER2-negative metastatic breast cancer (mBC) experiencing progression on a CDK4/6 inhibitor (CDK4/6i) and an aromatase inhibitor (AI) (35:09) Case: A woman in her early 70s with HR-positive, HER2-negative mBC that progresses on a CDK4/6i and an AI (41:16) CME information and select publications

Practical Perspectives: Current Management of Chronic Myeloid Leukemia | Faculty Presentation — Jorge Cortes, MD CME information and select publications

Featuring perspectives from Dr Bhavana (Tina) Bhatnagar, Dr Amanda Blackmon, Dr Jorge Cortes, Dr Michael J Mauro and Dr Neil P Shah, including the following topics: Recently presented data affecting the treatment of newly diagnosed chronic myeloid leukemia (CML) (0:00) Case: A man in his mid 40s with newly diagnosed CML with tyrosine kinase inhibitor (TKI) tolerability issues but a good response (24:51) Case: A woman in her mid 80s with chronic-phase CML (CP-CML) with translocation (9;22) (40:26) Case: A woman in her mid 80s with CP-CML and notable comorbidities (43:12) Case: A woman in her early 50s with CP-CML intolerant to dasatinib (51:22) Case: A woman in her late 50s with CP-CML and TKI withdrawal syndrome (1:01:22) Case: A woman in her mid 50s with accelerated-phase CML (1:08:22) Case: A woman in her early 70s with CP-CML and a suboptimal response to second-line TKI (1:17:00) Case: A man in his mid 30s with CP-CML and a complex variant Ph-positive translocation (1:23:24) Case: A man in his mid 30s with CP-CML and a T315I mutation (1:28:55) CME information and select publications

Featuring perspectives from Dr Jacob Sands, including the following topics: Introduction: A man in his mid 60s with a lung nodule on lung cancer screening (0:00) Current and Future Management of Small Cell Lung Cancer (15:42) CME information and select publications

Featuring perspectives from Dr Thierry Alcindor and Dr Mrinal Gounder, including the following topics: Introduction: Biology and Clinical Presentation (0:00) Case: A man in his mid 60s with desmoid fibromatosis — Dr Alcindor (12:36) Tyrosine Kinase Inhibitors (24:51) Gamma Secretase Inhibitors (31:02) Case: A woman in her early 40s with desmoid tumor treated with a gamma secretase inhibitor on a clinical trial — Dr Gounder (46:09) Case: A woman in her late 30s with a large groin desmoid tumor — Dr Gounder (51:52) Case: A woman in her early 30s with desmoid fibromatosis requiring treatment — Dr Alcindor (54:50) CME information and select publications

Featuring a slide presentation and related discussion from Dr Steven Horwitz, including the following topics: Front-line management of peripheral T-cell lymphomas (PCTLs) (0:00) Dose-intensified chemotherapy in combination with brentuximab vedotin for PTCL (9:59) Role of CD30 for PTCLs (14:36) Management of relapsed PTCL (20:40) CME information and select publications

Featuring an interview with Dr Steven Horwitz, including the following topics: Overview of peripheral T-cell lymphomas (PTCLs) (0:00) Efficacy and safety of brentuximab vedotin in the management of treatment-naïve and relapsed PTCLs (9:57) Emerging therapeutic strategies for PTCLs (19:48) Case: A man in his early 50s with CD30-positive anaplastic large cell lymphoma who experienced complete response (CR) to BV-CHP and continued remission after consolidation with autologous stem cell transplant (ASCT) (25:53) Management of ALK-positive anaplastic large cell lymphoma (32:14) Case: A man in his late 50s with CD8-positive PTCL not otherwise specified who achieved CR with CHOEP and experienced relapse after ASCT (34:33) Case: A woman in her early 70s with chemorefractory CD30-positive angioimmunoblastic T-cell lymphoma (38:26) Ongoing first-line studies for T-cell lymphomas; association of CAR T-cell therapy with T-cell malignancies (42:18) CME information and select publications

Featuring perspectives from Dr Edward B Garon and Dr Luis Paz-Ares, including the following topics: Introduction: Ivonescimab (0:00) First-Line Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Dr Garon (11:47) Promising Therapeutic Strategies for Patients with Progressive Metastatic NSCLC — Dr Paz-Ares (42:01) CME information and select publications

Featuring perspectives from Dr Matthew S Davids, including the following topics: Introduction: Is Chronic Lymphocytic Leukemia (CLL) the New Chronic Myeloid Leukemia? Cases We Didn't Hear About Last Week (0:00) Case: A man in his early 70s with IGHV-unmutated CLL (trisomy 12, del[17p]) receives ibrutinib for several years and is switched to acalabrutinib to lower the risk of cardiotoxicity — Warren S Brenner, MD (16:39) Case: A man in his mid 70s with relapsed atypical del(17p) CLL who previously received ibrutinib receives venetoclax/obinutuzumab — Bhavana (Tina) Bhatnagar, DO (22:10) Case: A woman in her early 80s with IGHV-mutated CLL begins treatment with zanubrutinib and 6 months later develops altered mental status due to cryptococcal meningitis — Erik Rupard, MD (33:00) Case: A woman in her early 80s with relapsed CLL (del[17p]/TP53 mutation) develops Stevens-Johnson syndrome while receiving ibrutinib — Spencer H Bachow, MD (38:21) Case: A man in his mid 90s with del(13q) CLL under observation for 12 years begins treatment with zanubrutinib and develops significant bruising/ecchymosis — Dr Rupard (41:14) Case: A woman in her late 70s with relapsed del(13q) CLL receives acalabrutinib and develops hyperleukocytosis — Dr Bhatnagar (45:44) Case: A woman in her mid 80s with rising white blood cell counts and asymptomatic recurrence of CLL (trisomy 12) receives rituximab with subsequent addition of venetoclax — Dr Brenner (50:20) Transformed CLL; CAR T-Cell Therapy (53:38) Journal Club with Dr Davids (54:26) CME information and select publications

Featuring perspectives from Dr Christopher Flowers, Prof Grzegorz S Nowakowski and Dr Laurie H Sehn, moderated by Dr Flowers, including the following topics: Introduction (0:00) Front-Line Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Sehn (1:56) Case: A woman in her late 40s with epidural DLBCL and a compression fracture (Dr Flowers) (12:45) Case: A woman in her late teens with primary intestinal large B-cell lymphoma (Dr Nowakowski)(16:51) Integration of Novel Agents into the Care of Patients with Relapsed/Refractory DLBCL — Dr Flowers (21:14) Case: A man in his late 70s diagnosed with DLBCL with recurrent disease (Dr Nowakowski) (29:38) Case: A woman in her mid 70s with multiple comorbidities diagnosed with DLBCL (Dr Sehn) (36:17) Bispecific Antibody Therapy for DLBCL — Dr Nowakowski (39:39) Case: A man in his late 50s with no comorbidities with recurrent DLBCL (Dr Sehn) (50:50) Case: A patient in their mid 50s with DLBCL who experiences disease relapse after R-CHOP and CAR-T therapies (Dr Flowers) (54:34) CME information and select publications

Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Corey J Langer, including the following topics: Introduction: A Model for Targeted Treatment in Non-Small Cell Lung Cancer (NSCLC) (0:00) NSCLC with ALK, ROS1 and NTRK Rearrangements — Dr Langer (9:10) Current and Future Treatment of Metastatic NSCLC with RET, MET, HER2 and KRAS Alterations — Dr Dagogo-Jack (34:22) CME information and select publications

Featuring perspectives from Dr Joshua Brody, Dr Matthew Lunning and Dr Jason Westin, moderated by Dr Lunning, including the following topics: Introduction (0:00) Integration of Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Westin (1:34) Current Role of CAR T-Cell Therapy for Other B-Cell Lymphomas — Dr Lunning (21:17) Tolerability and Other Practical Considerations with CAR T-Cell Therapy — Dr Brody (40:15) CME information and select publications

Featuring perspectives from Dr Joshua K Sabari and Dr Helena Yu, including the following topics: Introduction: Checkpoint Inhibitors and Lung Cancer with an EGFR Mutation (0:00) Current Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations — Dr Sabari (5:39) Novel Therapeutic Approaches for NSCLC Harboring EGFR Mutations — Dr Yu (28:21) CME information and select publications

Featuring a slide presentation and related discussion from Dr Tiffany A Traina, including the following topics: Extended follow-up with pembrolizumab/chemotherapy for patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC) (0:00) ASCENT trial: Survival advantage with sacituzumab govitecan versus physician's choice of chemotherapy for patients with relapsed/refractory TNBC (2:49) Treatment-associated side effects with sacituzumab govitecan (5:32) Activity of sacituzumab govitecan irrespective of TROP2 expression level and in patients with brain metastases (6:48) Ongoing Phase III studies evaluating sacituzumab govitecan in earlier lines of treatment (eg, ASCENT-03, ASCENT-04) (8:51) Efficacy and tolerability of trastuzumab deruxtecan in patients with HER2-low and HER2-ultralow metastatic breast cancer (10:26) Activity and ongoing investigations of other novel agents and strategies for mTNBC (20:05) CME information and select publications

Featuring an interview with Dr Tiffany A Traina, including the following topics: Choice of chemotherapy to combine with first-line pembrolizumab for metastatic triple-negative breast cancer (mTNBC) (0:00) Ongoing investigations of androgen receptor-targeting agents for metastatic breast cancer (mBC) (8:37) Efficacy and CNS activity of sacituzumab govitecan for mTNBC; monitoring and management of treatment-associated side effects (14:34) Activity and tolerability of enfortumab vedotin for mTNBC (21:47) Rationale for combining antibody-drug conjugates with other systemic therapies for TNBC; early data and ongoing research efforts with combination approaches (24:13) Selection and sequencing of therapeutic options for advanced breast cancer (26:36) Clinical activity of trastuzumab deruxtecan; spectrum, severity and management of treatment-emergent toxicities (32:00) Case: A woman in her early 60s with mTNBC receives first-line pembrolizumab/carboplatin/gemcitabine (35:32) Case: A woman in her late 30s with TNBC and a short disease-free interval with adjuvant therapy is found to have CNS metastases that are treated with sacituzumab govitecan (40:40) Case: A woman in her late 60s and practicing physician is diagnosed with HR-negative, HER2-low mBC (44:16) CME information and select publications

Featuring slide presentations and related discussion from Dr Lipika Goyal, Dr James J Harding, Dr Milind Javle and Dr Robin K (Katie) Kelley, including the following topics: Current Role of Immunotherapeutic Strategies for Advanced Biliary Tract Cancers (BTCs) — Dr Kelley (0:00) Case: A man in his late 60s with advanced distal cholangiocarcinoma treated with the TOPAZ-1 regimen (13:27) Case: A woman in her early 70s with recurrent gallbladder cancer with biliary obstruction (15:56) Targeting FGFR and IDH Alterations for Advanced BTCs — Dr Goyal (35:00) Case: A woman in her late 30s with FGFR2 fusion-positive intrahepatic cholangiocarcinoma (ICC) (54:25) Case: A man in his late 60s with cholangiocarcinoma metastases to liver and bone (1:01:33) Case: A woman in her 60s with ICC with an IDH1 mutation (1:10:05) Emerging Role of HER2-Targeted Therapy for Advanced BTCs — Dr Harding (1:21:15) Case: A man in his early 40s with cholangiocarcinoma metastatic to the appendix (1:57:25) New Directions in the Management of BTCs — Dr Javle (2:01:09) CME information and select publications

Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors | Faculty Presentation 2: Later-Line Treatment for Advanced NETs — Pamela Kunz, MD CME information and select publications

Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors | Faculty Presentation 1: First-Line Therapy for Advanced Neuroendocrine Tumors (NETs) — Simron Singh, MD, MPH CME information and select publications

Featuring perspectives from Dr Pamela Kunz and Dr Simron Singh, including the following topics: Introduction (0:00) Overview (4:04) Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors (NETs) (27:07) Multitarget Tyrosine Kinase Inhibitors for the Treatment of NETs (39:37) Other New Advances in the Management of NETs (50:29) CME information and select publications

Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers | Faculty Presentation 1: HER2-Targeted Strategies for HER2-Positive Gastroesophageal and Colorectal Cancers — John Strickler, MD CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr John Strickler, including the following topics: Introduction: Back-to-School Special (0:00) Biomarker Assays in Advanced Gastrointestinal (GI) Cancers (10:12) Sequencing of Treatment for HER2-Positive GI Cancers (28:37) Toxicities Associated with Anti-HER2 Treatment (48:32) Novel Agents and Strategies for HER2-Positive GI Cancers (58:10) CME information and select publications